Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.


Journal

BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741

Informations de publication

Date de publication:
11 2022
Historique:
revised: 22 04 2022
received: 22 09 2021
accepted: 16 05 2022
pubmed: 6 7 2022
medline: 19 10 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Ashkenazi-Jewish (AJ) population-based BRCA testing is acceptable, cost-effective and amplifies primary prevention for breast & ovarian cancer. However, data describing lifestyle impact are lacking. We report long-term results of population-based BRCA testing on lifestyle behaviour and cancer risk perception. Two-arm randomised controlled trials (ISRCTN73338115, GCaPPS): (a) population-screening (PS); (b) family history (FH)/clinical criteria testing. North London AJ-population. AJ women/men >18 years. prior BRCA testing or first-degree relatives of BRCA-carriers. Participants were recruited through self-referral. All participants received informed pre-test genetic counselling. The intervention included genetic testing for three AJ BRCA-mutations: 185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 6174delT(c.5946delT). This was undertaken for all participants in the PS arm and participants fulfilling FH/clinical criteria in the FH arm. Patients filled out customised/validated questionnaires at baseline/1-year/2-year/3-year follow-ups. Generalised linear-mixed models adjusted for covariates and appropriate contrast tests were used for between-group/within-group analysis of lifestyle and behavioural outcomes along with evaluating factors associated with these outcomes. Outcomes are adjusted for multiple testing (Bonferroni method), with P < 0.0039 considered significant. Lifestyle/behavioural outcomes at baseline/1-year/2-year/3-year follow-ups. 1034 participants were randomised to PS (n = 530) or FH (n = 504) arms. No significant difference was identified between PS- and FH-based BRCA testing approaches in terms of dietary fruit/vegetable/meat consumption, vitamin intake, alcohol quantity/ frequency, smoking behaviour (frequency/cessation), physical activity/exercise or routine breast mammogram screening behaviour, with outcomes not affected by BRCA test result. Cancer risk perception decreased with time following BRCA testing, with no difference between FH/PS approaches, and the perception of risk was lowest in BRCA-negative participants. Men consumed fewer fruits/vegetables/vitamins and more meat/alcohol than women (P < 0.001). Population-based and FH-based AJ BRCA testing have similar long-term lifestyle impacts on smoking, alcohol, dietary fruit/vegetable/meat/vitamin, exercise, breast screening participation and reduced cancer risk perception.

Identifiants

pubmed: 35781768
doi: 10.1111/1471-0528.17253
pmc: PMC9796935
doi:

Substances chimiques

Vitamins 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1970-1980

Subventions

Organisme : NHS Innovation Accelerator
ID : PT
Organisme : NIHR Biomedical Research Centre, University College London Hospitals
Organisme : The Eve Appeal
ID : GTCV
Organisme : Medical Research Council
ID : MC_UU_00004/01
Pays : United Kingdom

Informations de copyright

© 2022 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.

Références

J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
BJOG. 2022 Nov;129(12):1970-1980
pubmed: 35781768
J Gerontol A Biol Sci Med Sci. 2000 Oct;55(10):M613-7
pubmed: 11034235
PLoS One. 2014 Nov 14;9(11):e112665
pubmed: 25398084
J Genet Couns. 2007 Aug;16(4):433-56
pubmed: 17594133
Cancer Prev Res (Phila). 2020 Aug;13(8):643-648
pubmed: 32409595
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Genet Med. 2018 Nov;20(11):1446-1454
pubmed: 29595811
Fam Cancer. 2009;8(3):241-50
pubmed: 19184534
J R Soc Promot Health. 2007 Jan;127(1):38-44
pubmed: 17319316
J Med Genet. 2016 Jul;53(7):472-80
pubmed: 26993268
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Lifestyle Genom. 2018;11(1):49-63
pubmed: 29635250
Adv Pharm Bull. 2016 Dec;6(4):467-477
pubmed: 28101454
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):70-5
pubmed: 16434589
J Med Genet. 2018 Aug;55(8):538-545
pubmed: 29622727
Ann Behav Med. 2017 Oct;51(5):718-729
pubmed: 28290066
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:373-412
pubmed: 32315550
J Psychosoc Oncol. 2008;26(3):63-80
pubmed: 19042265
J Genet Couns. 2013 Oct;22(5):565-75
pubmed: 23547022
J Community Genet. 2018 Jan;9(1):1-18
pubmed: 28664264
J Natl Cancer Inst. 2014 Nov 30;107(1):379
pubmed: 25435541
Natl Vital Stat Rep. 2017 Nov;66(6):1-75
pubmed: 29235985
J Natl Cancer Inst. 2014 Nov 30;107(1):380
pubmed: 25435542
Am J Health Promot. 1995 May-Jun;9(5):352-60
pubmed: 10150767
J Am Coll Cardiol. 2017 Mar 7;69(9):1116-1125
pubmed: 28254173
BMJ Open. 2015 Sep 24;5(9):e008705
pubmed: 26408285
JACC Heart Fail. 2017 May;5(5):367-374
pubmed: 28396043
Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12
pubmed: 28690137
BJOG. 2020 Feb;127(3):364-375
pubmed: 31507061
BMJ Open. 2017 Dec 22;7(12):e017675
pubmed: 29275340
J Med Internet Res. 2016 Feb 05;18(2):e30
pubmed: 26851191
Ann Behav Med. 2004 Apr;27(2):107-16
pubmed: 15053018
J Genet Couns. 2007 Aug;16(4):457-68
pubmed: 17619128
BJOG. 2019 May;126(6):784-794
pubmed: 30767407
N Engl J Med. 2011 Feb 10;364(6):524-34
pubmed: 21226570
Aust N Z J Public Health. 2014 Aug;38(4):332-9
pubmed: 24962802
J Genet Couns. 2008 Aug;17(4):314-26
pubmed: 18481164
J Health Popul Nutr. 2007 Mar;25(1):47-61
pubmed: 17615903
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10
pubmed: 25192939
Addiction. 2009 Sep;104(9):1487-500
pubmed: 19686518
Psychol Health. 2011 Sep;26(9):1113-27
pubmed: 21929476
Clin Genet. 2010 Nov;78(5):411-7
pubmed: 20653694
Health Promot Int. 2015 Sep;30(3):736-45
pubmed: 23985248

Auteurs

Matthew Burnell (M)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

Faiza Gaba (F)

Wolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, London, UK.
Department of Gynaecological Oncology, Barts Health NH Trust, London, UK.

Monika Sobocan (M)

Wolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, London, UK.
Department of Gynaecological Oncology, Barts Health NH Trust, London, UK.

Rakshit Desai (R)

Department of Gynaecological Oncology, Barts Health NH Trust, London, UK.

Saskia Sanderson (S)

Behavioural Sciences Unit, Department Epidemiology and Public Health, University College London, London, UK.

Kelly Loggenberg (K)

Department Clinical Genetics, North East Thames Regional Genetics Unit, Great Ormond Street Hospital, London, UK.

Sue Gessler (S)

Department of Gynaecological Oncology, Institute for Women's Health, University College London, London, UK.

Lucy Side (L)

University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Angela F Brady (AF)

Department Clinical Genetics, North West Thames Regional Genetics Unit, Northwick Park Hospital, London, UK.

Huw Dorkins (H)

St Peter's College, University of Oxford, Oxford, UK.

Yvonne Wallis (Y)

West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK.
Depatment Clinical Genetics, West Midlands Regional Genetics Service, Birmingham Women's NHS Foundation Trust, Birmingham, UK.

Chris Jacobs (C)

Depatment Clinical Genetics, Guy's Hospital, London, UK.
University of Technology Sydney, Sydney, New South Wales, Australia.

Rosa Legood (R)

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.

Uziel Beller (U)

Department of Gynaecology, Shaare Zedek Medical Center, Jerusalem, Israel.

Ian Tomlinson (I)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Jane Wardle (J)

Behavioural Sciences Unit, Department Epidemiology and Public Health, University College London, London, UK.

Usha Menon (U)

Department of Gynaecological Oncology, Barts Health NH Trust, London, UK.

Ian Jacobs (I)

University of New South Wales, Sydney, New South Wales, Australia.

Ranjit Manchanda (R)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Wolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, London, UK.
Department of Gynaecological Oncology, Barts Health NH Trust, London, UK.
Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Department of Gynaecology, All India Institute of Medical Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH